BMS-816336

• Description:

  BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC50 of 3.0 nM[1].

• UNSPSC:

  12352005

• Target:

  11β-HSD

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/BMS-816336.html

• Purity:

  99.86

• Solubility:

  DMSO : 300 mg/mL (ultrasonic)

• Smiles:

  O[C@@H]1[C@H]2C[C@@H]3[C@@] (C4=CC=CC=C4) (CC (N5CC (O) C5) =O) [C@@H] (C[C@H]1C3) C2

• Molecular Formula:

  C21H27NO3

• Molecular Weight:

  341.44

• References & Citations:

  [1]Ye XY, et al. Discovery of Clinical Candidate 2- ((2S,6S) -2-Phenyl-6-hydroxyadamantan-2-yl) -1- (3'-hydroxyazetidin-1-yl) ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem. 2017 Jun 22;60 (12) :4932-4948.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  1009583-20-3